Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, utilizing its PRISM platform to develop treatments for disorders like Duchenne muscular dystrophy and Huntington’s disease. Founded in 2015, it employs 266 people and is advancing RNA-targeting modalities such as editing and interference.
Wave Life Sciences (WVE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Wave Life Sciences's actual EPS was $0.17, beating the estimate of -$0.18 per share, resulting in a 192.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
